Purpose: To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. Patients and Methods: A total of 1625 primary breast cancer patients who received post-surgery adj...Purpose: To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. Patients and Methods: A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital,China,from July 2002 to November 2005 were included in the study. Among them,600 patients were given CMF (CTX+MTX+5-Fu) regimen,600 given CEF (CTX+E-ADM+5-Fu) regimen,and 425 given anthracyclines plus taxanes regimen,with mean follow-up time of 42 months. Results: In CMF treatment group,the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%,P=0.0348); in node-positive subgroup,the 3-year DFS was 84.72% in HER2 over-expressed patients,and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen,anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative. Conclusion: HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemo-therapy,but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.展开更多
Overexpression of thioredoxin reductase has been identified in a variety of primary tumors, suggesting the levels of TrxR activity between tumor patients and normal people are potentially different. Here, we performed...Overexpression of thioredoxin reductase has been identified in a variety of primary tumors, suggesting the levels of TrxR activity between tumor patients and normal people are potentially different. Here, we performed a study to investigate the differences of TrxR activity between normal people and breast tumor patients, with the expectation that TrxR activity can be considered as a novel biomarker involved in breast cancer diagnosis and treatment. In this study, we have demonstrated for the first time that TrxR levels in breast cancer patients before therapy were significantly higher than those of normal people （P〈0.05）. No significant difference of TrxR activity was found among the patients at different stages of breast tumor progression. In the patient group of TrxR 〈10 U/mL, evaluation of TrxR activity has shown a high consistency with the results from cancer diagnostic imaging. Overall, these observations suggest TrxR as an effective biomarker to monitor and evaluate the clinical outcome of breast cancer therapeutics, and identify TrxR activity as a novel approach for breast cancer early-stage detection.展开更多
The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors.For this purpose, tumor-microenvironment stimuliresponsive materials have great potential. Here, we prepa...The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors.For this purpose, tumor-microenvironment stimuliresponsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol(HNK) and 5,6-dimethylxanthenone-4-acetic acid(DMXAA)to a glutathione(GSH)-responsive nanocarrier, poly(α-lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites,achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy.展开更多
文摘Purpose: To exam the relationship between HER2 over-expression and different adjuvant chemotherapies in breast cancer. Patients and Methods: A total of 1625 primary breast cancer patients who received post-surgery adjuvant chemotherapy in Tianjin Cancer Hospital,China,from July 2002 to November 2005 were included in the study. Among them,600 patients were given CMF (CTX+MTX+5-Fu) regimen,600 given CEF (CTX+E-ADM+5-Fu) regimen,and 425 given anthracyclines plus taxanes regimen,with mean follow-up time of 42 months. Results: In CMF treatment group,the 3-year disease free survival (DFS) in HER2 over-expressed patients was lower than that of the HER2-negative ones (89.80% vs 91.24%,P=0.0348); in node-positive subgroup,the 3-year DFS was 84.72% in HER2 over-expressed patients,and 90.18% in the HER-2-negative ones (P=0.0271). Compared to CMF regimen,anthracyclines and anthracyclines plus taxanes regimens are more effective (P<0.05) in node-positive HER2 over-expression than those in the node-negative. Conclusion: HER2 over-expression is an independent index for predicting poor prognosis and short DFS for breast cancer patients. HER2 over-expressed patients are resistant to CMF regimen chemo-therapy,but sensitive to anthracyclines-based or anthracyclines plus taxanes regimen. HER2 expression can be taken as a marker for therapies in breast cancer.
基金National Natural Science Foundation of China(Grant No.81372266)Foundation of Tianjin Binhai Science and Technology Plan(Grant No.2010BK160010)
文摘Overexpression of thioredoxin reductase has been identified in a variety of primary tumors, suggesting the levels of TrxR activity between tumor patients and normal people are potentially different. Here, we performed a study to investigate the differences of TrxR activity between normal people and breast tumor patients, with the expectation that TrxR activity can be considered as a novel biomarker involved in breast cancer diagnosis and treatment. In this study, we have demonstrated for the first time that TrxR levels in breast cancer patients before therapy were significantly higher than those of normal people （P〈0.05）. No significant difference of TrxR activity was found among the patients at different stages of breast tumor progression. In the patient group of TrxR 〈10 U/mL, evaluation of TrxR activity has shown a high consistency with the results from cancer diagnostic imaging. Overall, these observations suggest TrxR as an effective biomarker to monitor and evaluate the clinical outcome of breast cancer therapeutics, and identify TrxR activity as a novel approach for breast cancer early-stage detection.
基金supported by the Ministry of Science and Technology of China (2018ZX09711003-012)the National Natural Science Foundation of China (51873206, 51673189, 51829302, 51503202, 51833010 and 51520105004)the Program of Scientific Development of Jilin Province (20190103033JH)
文摘The key to improve the therapeutic efficacy for cancer treatment is to increase the delivery of drugs to tumors.For this purpose, tumor-microenvironment stimuliresponsive materials have great potential. Here, we prepared a new nanomedicine by bonding the conjugate of honokiol(HNK) and 5,6-dimethylxanthenone-4-acetic acid(DMXAA)to a glutathione(GSH)-responsive nanocarrier, poly(α-lipoic acid) polyethylene glycol. The nanomedicine would disintegrate due to the high level of GSH at the tumor sites,achieving the co-delivery of HNK and DMXAA, and realizing the combination therapy through close-range killing by HNK and long-range striking by DMXAA together. In a murine 4T1 breast tumor model, this strategy exhibited high tumor inhibition rate of 93%, and provided a valuable therapeutic choice for cancer therapy.
